Joseph Mikhael, MD, Translational Genomics Research Institute
Articles by Joseph Mikhael, MD, Translational Genomics Research Institute
Holistic and Multidisciplinary Approaches to Multiple Myeloma Management
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Impact of Clinical Trials on the Management of Multiple Myeloma
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.
Importance of Clinical Trial Enrollment in Multiple Myeloma
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.
Multiple Myeloma: Regulatory Aspects of Treatment Development and Approval
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.
Educating Patients on Treatment Options for Multiple Myeloma
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.
Treatment for Newly Diagnosed Multiple Myeloma: Addressing Disparities in Care
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.
Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.
Role of Diagnostic Testing in Patients with Multiple Myeloma
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.
Educating on Multiple Myeloma: Patient and Physician Resources
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Joseph Mikhael, MD, Translational Genomics Research Institute,Katie Joyner, Myeloma Patients Europe Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.
Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care
ByFaith E. Davies, MD, NYU Langone's Perlmutter Cancer Center,Joseph Mikhael, MD, Translational Genomics Research Institute,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Katie Joyner, Myeloma Patients Europe Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.
Investigational Agents for Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
CARTITUDE-1 and CARTITUDE-2 Trials in Multiple Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.
Using CAR T Therapy for Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.
Role of BCMA-Targeted Agents in Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.
Treatment of Relapsed/Refractory Myeloma: Novel Agents
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.
PI-Based Combinations for Relapsed Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.
Using IMiD-Based Strategies for Relapsed Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.
Approaching Treatment of Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.
Role of MRD Assessment in Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.
Improving Maintenance Therapy for Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.
High-Risk Multiple Myeloma: Selecting Initial Therapy
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.
Standard Induction for Newly Diagnosed Symptomatic Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.
Overview of Newly Diagnosed Multiple Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.
Educating on Multiple Myeloma: Patient and Physician Resources
Using IMiD-Based Strategies for Relapsed Myeloma
Role of Diagnostic Testing in Patients with Multiple Myeloma
Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care
Improving Maintenance Therapy for Myeloma
Treatment of Relapsed/Refractory Myeloma: Novel Agents